A methylation risk score for chronic kidney disease: a HyperGEN study.
Chronic kidney disease
Epigenetics
Methylation risk score
eGFR
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 Aug 2024
01 Aug 2024
Historique:
received:
24
04
2024
accepted:
24
07
2024
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
31
7
2024
Statut:
epublish
Résumé
Chronic kidney disease (CKD) impacts about 1 in 7 adults in the United States, but African Americans (AAs) carry a disproportionately higher burden of disease. Epigenetic modifications, such as DNA methylation at cytosine-phosphate-guanine (CpG) sites, have been linked to kidney function and may have clinical utility in predicting the risk of CKD. Given the dynamic relationship between the epigenome, environment, and disease, AAs may be especially sensitive to environment-driven methylation alterations. Moreover, risk models incorporating CpG methylation have been shown to predict disease across multiple racial groups. In this study, we developed a methylation risk score (MRS) for CKD in cohorts of AAs. We selected nine CpG sites that were previously reported to be associated with estimated glomerular filtration rate (eGFR) in epigenome-wide association studies to construct a MRS in the Hypertension Genetic Epidemiology Network (HyperGEN). In logistic mixed models, the MRS was significantly associated with prevalent CKD and was robust to multiple sensitivity analyses, including CKD risk factors. There was modest replication in validation cohorts. In summary, we demonstrated that an eGFR-based CpG score is an independent predictor of prevalent CKD, suggesting that MRS should be further investigated for clinical utility in evaluating CKD risk and progression.
Identifiants
pubmed: 39085340
doi: 10.1038/s41598-024-68470-z
pii: 10.1038/s41598-024-68470-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17757Subventions
Organisme : NIDDK NIH HHS
ID : F31DK128990
Pays : United States
Organisme : NIDDK NIH HHS
ID : T32DK116672
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01HL055673
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35HL155466
Pays : United States
Organisme : NIEHS NIH HHS
ID : R01ES020836
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Prevention, C. F. D. C. a. Chronic Kidney Disease in the United States, 2021. (Atlanta, GA, 2021).
System, U. S. R. D. 2020 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. (National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD).
Laster, M., Shen, J. I. & Norris, K. C. Kidney disease among African Americans: A population perspective. Am. J. Kidney Dis. 72, S3–S7. https://doi.org/10.1053/j.ajkd.2018.06.021 (2018).
doi: 10.1053/j.ajkd.2018.06.021
pubmed: 30343720
pmcid: 6200351
Vart, P., van Zon, S. K. R., Gansevoort, R. T., Bultmann, U. & Reijneveld, S. A. SES, chronic kidney disease, and race in the U.S.: A systematic review and meta-analysis. Am. J. Prev. Med. 53, 730–739. https://doi.org/10.1016/j.amepre.2017.06.036 (2017).
doi: 10.1016/j.amepre.2017.06.036
pubmed: 28869090
Vart, P. et al. National trends in the prevalence of chronic kidney disease among racial/ethnic and socioeconomic status groups, 1988–2016. JAMA Netw. Open 3, e207932. https://doi.org/10.1001/jamanetworkopen.2020.7932 (2020).
doi: 10.1001/jamanetworkopen.2020.7932
pubmed: 32672828
pmcid: 7366187
Zhang, J., Thio, C. H. L., Gansevoort, R. T. & Snieder, H. Familial aggregation of CKD and heritability of kidney biomarkers in the general population: The lifelines cohort study. Am. J. Kidney Dis. 77, 869–878. https://doi.org/10.1053/j.ajkd.2020.11.012 (2021).
doi: 10.1053/j.ajkd.2020.11.012
pubmed: 33359149
Canadas-Garre, M. et al. Genetic susceptibility to chronic kidney disease—Some more pieces for the heritability puzzle. Front. Genet. 10, 453. https://doi.org/10.3389/fgene.2019.00453 (2019).
doi: 10.3389/fgene.2019.00453
pubmed: 31214239
pmcid: 6554557
Jefferis, J., Pelecanos, A., Catts, V. & Mallett, A. The heritability of kidney function using an older Australian twin population. Kidney Int. Rep. 7, 1819–1830. https://doi.org/10.1016/j.ekir.2022.05.012 (2022).
doi: 10.1016/j.ekir.2022.05.012
pubmed: 35967118
pmcid: 9366362
Freedman, B. I., Limou, S., Ma, L. & Kopp, J. B. APOL1-associated nephropathy: A key contributor to racial disparities in CKD. Am. J. Kidney Dis. 72, S8–S16. https://doi.org/10.1053/j.ajkd.2018.06.020 (2018).
doi: 10.1053/j.ajkd.2018.06.020
pubmed: 30343724
pmcid: 6200346
Pattaro, C. et al. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. Nat. Commun. 7, 10023. https://doi.org/10.1038/ncomms10023 (2016).
doi: 10.1038/ncomms10023
pubmed: 26831199
pmcid: 4735748
Khan, A. et al. Genome-wide polygenic score to predict chronic kidney disease across ancestries. Nat. Med. 28, 1412–1420. https://doi.org/10.1038/s41591-022-01869-1 (2022).
doi: 10.1038/s41591-022-01869-1
pubmed: 35710995
pmcid: 9329233
Ma, J., Yang, Q., Hwang, S. J., Fox, C. S. & Chu, A. Y. Genetic risk score and risk of stage 3 chronic kidney disease. BMC Nephrol. 18, 32. https://doi.org/10.1186/s12882-017-0439-3 (2017).
doi: 10.1186/s12882-017-0439-3
pubmed: 28103844
pmcid: 5248454
Thio, C. H. L. et al. Evaluation of a genetic risk score based on creatinine-estimated glomerular filtration rate and its association with kidney outcomes. Nephrol. Dial. Transplant 33, 1757–1764. https://doi.org/10.1093/ndt/gfx337 (2018).
doi: 10.1093/ndt/gfx337
pubmed: 29294079
Yun, S. et al. Genetic risk score raises the risk of incidence of chronic kidney disease in Korean general population-based cohort. Clin. Exp. Nephrol. 23, 995–1003. https://doi.org/10.1007/s10157-019-01731-8 (2019).
doi: 10.1007/s10157-019-01731-8
pubmed: 30955190
Zusi, C. et al. A renal genetic risk score (GRS) is associated with kidney dysfunction in people with type 2 diabetes. Diabetes. Res. Clin. Pract. 144, 137–143. https://doi.org/10.1016/j.diabres.2018.08.013 (2018).
doi: 10.1016/j.diabres.2018.08.013
pubmed: 30153470
Chu, A. Y. et al. Epigenome-wide association studies identify DNA methylation associated with kidney function. Nat. Commun. 8, 1286. https://doi.org/10.1038/s41467-017-01297-7 (2017).
doi: 10.1038/s41467-017-01297-7
pubmed: 29097680
pmcid: 5668367
Ammous, F. et al. Epigenome-wide association study identifies DNA methylation sites associated with target organ damage in older African Americans. Epigenetics 16, 862–875. https://doi.org/10.1080/15592294.2020.1827717 (2021).
doi: 10.1080/15592294.2020.1827717
pubmed: 33100131
Chen, J. et al. Epigenetic associations with estimated glomerular filtration rate among men with human immunodeficiency virus infection. Clin. Infect Dis. 70, 667–673. https://doi.org/10.1093/cid/ciz240 (2020).
doi: 10.1093/cid/ciz240
pubmed: 30893429
Lecamwasam, A. et al. DNA methylation profiling identifies epigenetic differences between early versus late stages of diabetic chronic kidney disease. Nephrol. Dial. Transplant https://doi.org/10.1093/ndt/gfaa226 (2020).
doi: 10.1093/ndt/gfaa226
Schlosser, P. et al. Meta-analyses identify DNA methylation associated with kidney function and damage. Nat. Commun. 12, 7174. https://doi.org/10.1038/s41467-021-27234-3 (2021).
doi: 10.1038/s41467-021-27234-3
pubmed: 34887417
pmcid: 8660832
Giurgescu, C. et al. Neighborhood environment and DNA methylation: Implications for cardiovascular disease risk. J. Urban Health 96, 23–34. https://doi.org/10.1007/s11524-018-00341-1 (2019).
doi: 10.1007/s11524-018-00341-1
pubmed: 30635842
pmcid: 6430282
Czamara, D. et al. Effects of stressful life-events on DNA methylation in panic disorder and major depressive disorder. Clin. Epigenetics 14, 55. https://doi.org/10.1186/s13148-022-01274-y (2022).
doi: 10.1186/s13148-022-01274-y
pubmed: 35477560
pmcid: 9047302
Yan, Q. et al. Exposure to violence, chronic stress, nasal DNA methylation, and atopic asthma in children. Pediatr. Pulmonol. 56, 1896–1905. https://doi.org/10.1002/ppul.25372 (2021).
doi: 10.1002/ppul.25372
pubmed: 33751861
pmcid: 8217314
Martin, E. M. & Fry, R. C. Environmental influences on the epigenome: Exposure- associated DNA methylation in human populations. Ann. Rev. Public Health 39, 309–333. https://doi.org/10.1146/annurev-publhealth-040617-014629 (2018).
doi: 10.1146/annurev-publhealth-040617-014629
Liu, H. et al. Epigenomic and transcriptomic analyses define core cell types, genes and targetable mechanisms for kidney disease. Nat. Genet. 54, 950–962. https://doi.org/10.1038/s41588-022-01097-w (2022).
doi: 10.1038/s41588-022-01097-w
pubmed: 35710981
Hidalgo, B. A. et al. A 6-CpG validated methylation risk score model for metabolic syndrome: The HyperGEN and GOLDN studies. PLoS One 16, e0259836. https://doi.org/10.1371/journal.pone.0259836 (2021).
doi: 10.1371/journal.pone.0259836
pubmed: 34780523
pmcid: 8592434
Chang, W. L. et al. A six-CpG panel with DNA methylation biomarkers predicting treatment response of chemoradiation in esophageal squamous cell carcinoma. J. Gastroenterol. 52, 705–714. https://doi.org/10.1007/s00535-016-1265-2 (2017).
doi: 10.1007/s00535-016-1265-2
pubmed: 27671002
van der Laan, L. C. et al. Epigenome-wide association study for perceived discrimination among sub-Saharan African migrants in Europe—The RODAM study. Sci. Rep. 10, 4919. https://doi.org/10.1038/s41598-020-61649-0 (2020).
doi: 10.1038/s41598-020-61649-0
pubmed: 32188935
pmcid: 7080832
de Barcelona Mendoza, V., Huang, Y., Crusto, C. A., Sun, Y. V. & Taylor, J. Y. Perceived racial discrimination and DNA methylation among african american women in the InterGEN study. Biol. Res. Nurs. 20, 145–152. https://doi.org/10.1177/1099800417748759 (2018).
doi: 10.1177/1099800417748759
Gottschalk, M. G., Domschke, K. & Schiele, M. A. Epigenetics underlying susceptibility and resilience relating to daily life stress, work stress, and socioeconomic status. Front. Psychiatry 11, 163. https://doi.org/10.3389/fpsyt.2020.00163 (2020).
doi: 10.3389/fpsyt.2020.00163
pubmed: 32265751
pmcid: 7099635
Qiu, C. et al. Cytosine methylation predicts renal function decline in American Indians. Kidney Int. 93, 1417–1431. https://doi.org/10.1016/j.kint.2018.01.036 (2018).
doi: 10.1016/j.kint.2018.01.036
pubmed: 29709239
pmcid: 5973533
Breeze, C. E. et al. Epigenome-wide association study of kidney function identifies trans-ethnic and ethnic-specific loci. Genome. Med. 13, 74. https://doi.org/10.1186/s13073-021-00877-z (2021).
doi: 10.1186/s13073-021-00877-z
pubmed: 33931109
pmcid: 8088054
Ahmad, A. S. et al. A novel DNA methylation score accurately predicts death from prostate cancer in men with low to intermediate clinical risk factors. Oncotarget 7, 71833–71840. https://doi.org/10.18632/oncotarget.12377 (2016).
doi: 10.18632/oncotarget.12377
pubmed: 27708246
pmcid: 5342126
Cheol Kim, D. et al. Quantitative DNA methylation and recurrence of breast cancer: A study of 30 candidate genes. Cancer Biomark. 11, 75–88. https://doi.org/10.3233/CBM-2012-0266 (2012).
doi: 10.3233/CBM-2012-0266
pubmed: 23011154
Barbu, M. C. et al. Epigenetic prediction of major depressive disorder. Mol. Psychiatry 26, 5112–5123. https://doi.org/10.1038/s41380-020-0808-3 (2021).
doi: 10.1038/s41380-020-0808-3
pubmed: 32523041
Zhu, X., Ma, X. & Wu, C. A methylomics-correlated nomogram predicts the recurrence free survival risk of kidney renal clear cell carcinoma. Math. Biosci. Eng. 18, 8559–8576. https://doi.org/10.3934/mbe.2021424 (2021).
doi: 10.3934/mbe.2021424
pubmed: 34814313
Dugué, P. A. et al. Methylation scores for smoking, alcohol consumption, and body mass index and risk of seven types of cancer. Int. J. Cancer. https://doi.org/10.1002/ijc.34513 (2023).
doi: 10.1002/ijc.34513
pubmed: 37387529
Zhou, J. et al. A risk score model based on nine differentially methylated mrnas for predicting prognosis of patients with clear cell renal cell carcinoma. Dis. Markers 2021, 8863799. https://doi.org/10.1155/2021/8863799 (2021).
doi: 10.1155/2021/8863799
pubmed: 33510822
pmcid: 7822694
Wei, J. H. et al. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. Nat. Commun. 6, 8699. https://doi.org/10.1038/ncomms9699 (2015).
doi: 10.1038/ncomms9699
pubmed: 26515236
pmcid: 4846314
Cappozzo, A. et al. A blood DNA methylation biomarker for predicting short-term risk of cardiovascular events. Clin. Epigenetics 14, 121. https://doi.org/10.1186/s13148-022-01341-4 (2022).
doi: 10.1186/s13148-022-01341-4
pubmed: 36175966
pmcid: 9521011
Lu, A. K. et al. DNA methylation signature aberration as potential biomarkers in treatment-resistant schizophrenia: Constructing a methylation risk score using a machine learning method. J. Psychiatr. Res. 157, 57–65. https://doi.org/10.1016/j.jpsychires.2022.11.008 (2022).
doi: 10.1016/j.jpsychires.2022.11.008
pubmed: 36442407
Chen, J. et al. Pruning and thresholding approach for methylation risk scores in multi-ancestry populations. Epigenetics 18, 2187172. https://doi.org/10.1080/15592294.2023.2187172 (2023).
doi: 10.1080/15592294.2023.2187172
pubmed: 36908043
pmcid: 10026878
Hao, L. et al. Development of a clinical polygenic risk score assay and reporting workflow. Nat. Med. https://doi.org/10.1038/s41591-022-01767-6 (2022).
doi: 10.1038/s41591-022-01767-6
pubmed: 35437332
pmcid: 9117136
Huls, A. & Czamara, D. Methodological challenges in constructing DNA methylation risk scores. Epigenetics 15, 1–11. https://doi.org/10.1080/15592294.2019.1644879 (2020).
doi: 10.1080/15592294.2019.1644879
pubmed: 31318318
Matías-García, P. R. et al. DNAm-based signatures of accelerated aging and mortality in blood are associated with low renal function. Clin. Epigenetics 13, 121. https://doi.org/10.1186/s13148-021-01082-w (2021).
doi: 10.1186/s13148-021-01082-w
pubmed: 34078457
pmcid: 8170969
Kalinowski, J. et al. Stress overload and DNA methylation in African American women in the intergenerational impact of genetic and psychological factors on blood pressure study. Epigenet Insights 15, 25168657221126310. https://doi.org/10.1177/25168657221126314 (2022).
doi: 10.1177/25168657221126314
pubmed: 36246163
pmcid: 9554129
Ramspek, C. L. et al. Kidney failure prediction models: A comprehensive external validation study in patients with advanced CKD. J. Am. Soc. Nephrol. 32, 1174–1186. https://doi.org/10.1681/ASN.2020071077 (2021).
doi: 10.1681/ASN.2020071077
pubmed: 33685974
pmcid: 8259669
Levey, A. S. et al. Nomenclature for kidney function and disease: executive summary and glossary from a kidney disease: Improving global outcomes (KDIGO) consensus conference. Kidney Dis. (Basel) 6, 309–317. https://doi.org/10.1159/000509359 (2020).
doi: 10.1159/000509359
pubmed: 33490111
Inker, L. A. et al. New creatinine- and cystatin c-based equations to estimate GFR without race. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2102953 (2021).
doi: 10.1056/NEJMoa2102953
pubmed: 34554658
pmcid: 8822996
Smyth, L. J., McKay, G. J., Maxwell, A. P. & McKnight, A. J. DNA hypermethylation and DNA hypomethylation is present at different loci in chronic kidney disease. Epigenetics 9, 366–376. https://doi.org/10.4161/epi.27161 (2014).
doi: 10.4161/epi.27161
pubmed: 24253112
Smyth, L. J. et al. Assessment of differentially methylated loci in individuals with end-stage kidney disease attributed to diabetic kidney disease: An exploratory study. Clin. Epigenetics 13, 99. https://doi.org/10.1186/s13148-021-01081-x (2021).
doi: 10.1186/s13148-021-01081-x
pubmed: 33933144
pmcid: 8088646
Houseman, E. A. et al. DNA methylation arrays as surrogate measures of cell mixture distribution. BMC Bioinform. 13, 86. https://doi.org/10.1186/1471-2105-13-86 (2012).
doi: 10.1186/1471-2105-13-86
Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol. 14, R115. https://doi.org/10.1186/gb-2013-14-10-r115 (2013).
doi: 10.1186/gb-2013-14-10-r115
pubmed: 24138928
pmcid: 4015143
Zhang, Y. et al. DNA methylation signatures in peripheral blood strongly predict all-cause mortality. Nat. Commun. 8, 14617. https://doi.org/10.1038/ncomms14617 (2017).
doi: 10.1038/ncomms14617
pubmed: 28303888
pmcid: 5357865
Diez Roux, A. V. et al. Neighborhood of residence and incidence of coronary heart disease. N. Engl. J. Med. 345, 99–106. https://doi.org/10.1056/NEJM200107123450205 (2001).
doi: 10.1056/NEJM200107123450205
pubmed: 11450679